Evidence map›Paper›PMID 39744098›Full record

ArticleNanotheranostics2025

Development and optimization of dapagliflozin oral nano-bilosomes using response surface method:

Ananda Kumar Chettupalli, Nihar Ranjan Kar, V T Iswariya, Uttam Prasad Panigrahy, Laliteshwar Pratap Singh, Harekrishna Roy, Deepadarshan Urs, Muralidharan V, Sandhya Rani Mandadi, M Akiful Haque and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanotheranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ananda Kumar ChettupalliDepartment of Pharmaceutical Siences, School of Pharmacy, Galgotias University, Greater Noida, Uttar Pradesh 203201, India.
Nihar Ranjan KarCenturion University of Technology and Management, Odisha, India.
V T IswariyaCMR College of Pharmacy, Kandlakoya, Medchal, Telangana, India.
Uttam Prasad PanigrahyFaculty of Pharmaceutical Science, Assam Down Town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, 781026, India.
Laliteshwar Pratap SinghNarayan Institute of Pharmacy, Gopal Narayan Singh University, Sasaram, Bihar, India.
Harekrishna RoyDepartment of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri, Guntur, Andhra Pradesh, India.
Deepadarshan UrsInflammation Research Laboratory, Department of Studies and Research in Biochemistry, Mangalore University, Karnataka, India.
Muralidharan VVishnu Institute of Pharmaceutical Education and Research, Narsapur, Telangana, India.
Sandhya Rani MandadiVishnu Institute of Pharmaceutical Education and Research, Narsapur, Telangana, India.
M Akiful HaqueDepartment of Pharmaceutical Siences, School of Pharmacy, Galgotias University, Greater Noida, Uttar Pradesh 203201, India.
Ritesh RanaHimachal Institute of Pharmaceutical Education and Research, Nadaun, Himachal Pradesh, India.
Talha Bin EmranDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In treating type 2 diabetes, avoiding glucose reabsorption (glucotoxicity) and managing hyperglycemia are also important. A metabolic condition known as diabetes (type-2) is characterized by high blood sugar levels in comparison to normal Bilosomes (BLs) containing Dapagliflozin (Dapa) were formulated, optimized, and tested for oral therapeutic efficacy in the current investigation. Used the Box Behnken design to optimize the Dapa-BLs, formulated via a thin-film hydration technique. Bile salts (X1) concentration, edge activator (X2) in mg, and non-ionic surfactant (X3) were the independent variables. The Entrapment Efficiency (Y1), Particle size (PS), polydispersity index (PDI), and zeta potential (ZP), were selected as dependent variables. To get the optimal formula, use Design-Expert® software for numerical optimization. The optimal bilosomal formula was selected by boosting %EE, ZP (absolute value), and

Indexed as

Benzhydryl CompoundsGlucosidesParticle SizeAdministration, OralAnimalsDiabetes Mellitus, Type 2Drug LiberationHypoglycemic AgentsLiposomesMaleNanoparticlesRatsRats, WistarSkin AbsorptionBenzhydryl CompoundsdapagliflozinGlucosidesHypoglycemic AgentsLiposomesDapagliflozinEdge activatorglucotoxicityhyperglycemiaNano BilosomesPermeation study

Identifiers

PMID39744098
PMCPMC11667563

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.